{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:44:17Z","timestamp":1788965057037,"version":"build-2803163510"},"reference-count":85,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Advanced hepatocellular carcinoma (HCC) is a serious condition associated with significant morbidity and mortality. Over the past few decades, however, this has drastically changed, primarily attributed to the development of new treatments, including tyrosine-kinase inhibitors (TKIs), vascular endothelial growth factor (VEGF) inhibitors, and immune checkpoint inhibitors (ICIs). This study aims to highlight the financial toxicity (FT) of advanced HCC treatments, across diverse healthcare systems and particularly in low- and middle-income countries (LMICs). We also aim to explore potential solutions to improve access to life-saving therapies such as ICIs. We conducted an exploratory targeted review of the current literature focusing on therapeutic advancements, their accessibility, and innovative strategies to overcome FT. The review particularly addresses barriers faced in LMICs and examines initiatives that could optimize ICI availability. Findings suggest that FT significantly limits access to ICIs globally, with heightened impact in resource-limited settings and increasingly recognized in high-income countries as well. This challenge is particularly severe in LMICs, where the high incidence of HCC is compounded by the unaffordability of effective treatments, creating a significant barrier to care. Key strategies to mitigate this include cost-saving measures such as dose rounding, vial sharing, lower dosage regimens, extended dosing intervals, and shorter treatment durations. Evidence from emerging studies, predominantly in non-HCC malignancies, suggests these measures may be tolerated without unexpected safety signals. However, HCC-specific prospective data remain limited, and these approaches are entirely off-label requiring further research. Addressing financial barriers to ICI access is essential for improving outcomes in advanced HCC, globally and particularly in LMICs. Global adoption of cost-saving strategies could enhance equitable access to innovative treatments, warranting further research and collaboration among stakeholders from both high- and low-income nations.<\/jats:p>","DOI":"10.1177\/10732748251399259","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:43:28Z","timestamp":1764193408000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Extent and Mitigation of Financial Toxicity of Immune Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-7987","authenticated-orcid":false,"given":"Nabil E.","family":"Omar","sequence":"first","affiliation":[{"name":"National Centre for Cancer Care and Research"},{"name":"Clinical and Population Health Research Program, College of Pharmacy, QU Health, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Elewa","sequence":"additional","affiliation":[{"name":"Qatar University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem A.","family":"El-Fass","sequence":"additional","affiliation":[{"name":"Syreon Middle East"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[{"name":"University of Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Dermime","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"},{"name":"College of Health Sciences, QU Health, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoud","family":"Al-Badriyeh","sequence":"additional","affiliation":[{"name":"Qatar University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Abushanab","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Hamad","sequence":"additional","affiliation":[{"name":"National Centre for Cancer Care and Research"},{"name":"Qatar University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70211-5"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15251"},{"key":"e_1_3_4_6_2","unstructured":"World bank open data | data. Accessed October 23 2022. https:\/\/data.worldbank.org\/"},{"key":"e_1_3_4_7_2","unstructured":"Knaul FM Frenk J Shulman L for the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries. Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries. Harvard Global Equity Initiative; 2011. https:\/\/gtfccc.harvard.edu. Accessed June 17 2024."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/jgo.2016.005363"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_155975"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2021.6987"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30161-3"},{"key":"e_1_3_4_12_2","first-page":"1","article-title":"Planning and developing population-based cancer registration in Low- or middle-income settings","volume":"43","author":"Bray F","year":"2014","unstructured":"Bray F, Znaor A, Cueva P, et al. Planning and developing population-based cancer registration in Low- or middle-income settings. Plan Dev Popul Cancer Regist Low- or Middle-Income Settings. 2014;43:1-46.","journal-title":"Plan Dev Popul Cancer Regist Low- or Middle-Income Settings"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102992"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDZ140"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/FPUBH.2023.1266533"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJW205"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1534"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn103"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v15.i4.544"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00787-x"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1379622\/BIBTEX"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0669"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_431272"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0708857"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000520095"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0026"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01159-1"},{"key":"e_1_3_4_30_2","unstructured":"Benson AB Abbott DE Anaya DA et al. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2022. National Comprehensive Cancer Network; 2022. https:\/\/www.nccn.org. Accessed October 25 2022."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33767"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-021-01498-z"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2021.15"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33211"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-022-00097-5"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-021-00672-2"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0433-1"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2009.187"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.05.020"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1552432"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2018.10.003"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-019-0112-4"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/S12904-020-00558-5"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/CAM4.6375"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3322\/CA.2007.0011"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100269"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07044-z"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06952-4"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3617"},{"key":"e_1_3_4_50_2","volume-title":"Out-of-pocket expenditure (% of current health expenditure) - lower middle income | data","author":"The World Bank","year":"2021","unstructured":"The World Bank. Out-of-pocket expenditure (% of current health expenditure) - lower middle income | data. Data. 2021. https:\/\/data.worldbank.org\/indicator\/SH.XPD.OOPC.CH.ZS?end=2019&locations=XO&start=2000&view=chart. Accessed October 29, 2022."},{"issue":"2","key":"e_1_3_4_51_2","first-page":"SP61","article-title":"Humanistic and economic burden of hepatocellular carcinoma: systematic literature review","volume":"25","author":"Kohn CG","year":"2019","unstructured":"Kohn CG, Singh P, Korytowsky B, et al. Humanistic and economic burden of hepatocellular carcinoma: systematic literature review. Am J Manag Care. 2019;25(2):SP61-SP73.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_52_2","unstructured":"Red Book: Micromedex. IBM Watson Health; 2022. https:\/\/www.micromedexsolutions.com. Accessed October 28 2022."},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.6.572"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/S12072-008-9054-5"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14182"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/S12889-020-8282-Z\/TABLES\/3"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/S41571-022-00700-7"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/BMJGH-2024-017133"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00439"},{"key":"e_1_3_4_60_2","unstructured":"Expert consultation meeting on cancer medicine candidates for the 2025 model lists of essential medicines 23-24 January 2025 evaluations and advice for the expert committee on the selection and use of essential medicines 2."},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.025411"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211024723"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1136043"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e14009"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0177-2"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03971-7"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03954-8"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000332"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33534"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1159\/000512000"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2888"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051157"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx063"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.932212"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad061"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/S40273-025-01535-7"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906251"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030682"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00102"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33868"},{"key":"e_1_3_4_82_2","doi-asserted-by":"crossref","unstructured":"Van den Heuvel M Van der Noort V Ter Heine R et al. Low dose versus standard dose pembrolizumab for treatment of stage IV non-small cell lung carcinoma: results of the pre-planned interim analysis of the NVALT-30 clinical trial. In: Presented At: 2024 ESMO Congress September 13-17 2024 Barcelona Spain.","DOI":"10.1016\/j.annonc.2024.08.1315"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1186\/S13063-025-08726-9"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.003"},{"key":"e_1_3_4_85_2","unstructured":"Research consortia & collaborative research groups | EGRP\/DCCPS\/NCI\/NIH. Accessed September 12 2025.https:\/\/epi.grants.cancer.gov\/Consortia\/"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0532-4"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251399259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748251399259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251399259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:24:13Z","timestamp":1777386253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748251399259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":85,"alternative-id":["10.1177\/10732748251399259"],"URL":"https:\/\/doi.org\/10.1177\/10732748251399259","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748251399259\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251399259\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251399259\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251399259\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251399259\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251399259\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251399259\/v2\/response1","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"10732748251399259"}}